Pfizer Inc. (NYSE:PFE) Holdings Raised by Heartland Bank & Trust Co

Heartland Bank & Trust Co lifted its stake in Pfizer Inc. (NYSE:PFEFree Report) by 64.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,860 shares of the biopharmaceutical company’s stock after acquiring an additional 5,409 shares during the quarter. Heartland Bank & Trust Co’s holdings in Pfizer were worth $399,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank bought a new stake in Pfizer during the fourth quarter valued at about $3,150,472,000. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley lifted its position in shares of Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Pfizer during the 1st quarter valued at approximately $311,238,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.3 %

Shares of PFE stock traded down $0.08 during trading hours on Wednesday, hitting $27.47. 13,389,246 shares of the company were exchanged, compared to its average volume of 42,908,938. The business has a 50 day moving average of $27.41 and a two-hundred day moving average of $29.25. The company has a market capitalization of $155.55 billion, a PE ratio of 76.11, a PEG ratio of 1.24 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. Analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on PFE shares. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. UBS Group decreased their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Truist Financial lowered their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $36.88.

Get Our Latest Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.